On July 21, 2022 Shiyan Lake International LP Summit Forum was held in Shenzhen International Convention and Exhibition Center. At the meeting, Shenzhen Venture Capital Association officially released the [Greater Bay Area High Growth Enterprises TOP50 List], focusing on the three major tracks of Big Health, Big Information and Big Manufacturing. After five months of recommendation by investment institutions and centralized scoring and evaluation by investors of each track, the list of fifty high-growth enterprises was finally determined.

META Pharmaceuticals, as the first company in China to pioneer original drug discovery and development based on a novel biological theory of immune metabolism, is dedicated to unraveling the intricate biological mechanisms through which immune cells and nutrient metabolism mutually influence each other. Our mission is to achieve breakthroughs in therapeutic strategies that regulate immune system function by modulating the metabolic vitality of immune cells. Driven by this vision, META Pharmaceuticals has made significant progress in its preclinical pipeline. Leveraging cutting-edge research and innovative approaches, we are developing first-in-class drugs targeting immunometabolism. Our commitment to advancing these therapeutic solutions has garnered recognition, and we are proud to have been selected as one of the top 50 high-growth companies in the Greater Bay Area for 2022.

【大湾区高成长性企业TOP50】榜单如下：